PMID- 32918350
OWN - NLM
STAT- MEDLINE
DCOM- 20210701
LR  - 20210701
IS  - 1523-5378 (Electronic)
IS  - 1083-4389 (Linking)
VI  - 25 Suppl 1
DP  - 2020 Sep
TI  - Review - Treatment of Helicobacter pylori infection 2020.
PG  - e12743
LID - 10.1111/hel.12743 [doi]
AB  - This review summarizes important studies regarding Helicobacter pylori therapy 
      published from April 2019 to April 2020. The main themes that emerge involve 
      studies assessing antibiotic resistance, and there is also growing momentum 
      behind the utility of vonoprazan as an alternative to proton pump inhibitor (PPI) 
      therapy and also bismuth-based regimens as a first-line regimen. Antibiotic 
      resistance is rising wherever it is being assessed, and clarithromycin resistance 
      in particular has reached a point where it may no longer be a viable therapy 
      without previous testing in many regions of the world. The evidence for the 
      efficacy of a bismuth-based quadruple therapy as a first-line therapy is now very 
      clearly established, and there is substantial evidence that it is the best 
      performing first-line therapy. The utility of vonoprazan as an alternative to PPI 
      therapy, especially in resistant and difficult-to-treat groups, has also been 
      considered in great detail this year, and it may offer an opportunity in the near 
      future to reduce the problem of antibiotic resistance.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - O'Connor, Anthony
AU  - O'Connor A
AD  - Department of Gastroenterology, Tallaght University Hospital/Trinity College, 
      Dublin, Ireland.
FAU - Furuta, Takahisa
AU  - Furuta T
AD  - The Center for Clinical Research, Hamamatsu University School of Medicine, 
      Hamamatsu, Japan.
FAU - Gisbert, Javier P
AU  - Gisbert JP
AD  - Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de 
      Investigacion Sanitaria Princesa (IIS-IP), Universidad Autonoma de Madrid (UAM), 
      Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas 
      (CIBEREHD), Madrid, Spain.
FAU - O'Morain, Colm
AU  - O'Morain C
AD  - Department of Gastroenterology, Tallaght University Hospital/Trinity College, 
      Dublin, Ireland.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Helicobacter
JT  - Helicobacter
JID - 9605411
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - U015TT5I8H (Bismuth)
SB  - IM
MH  - *Anti-Bacterial Agents/pharmacology/therapeutic use
MH  - *Bismuth/pharmacology/therapeutic use
MH  - *Drug Resistance, Bacterial
MH  - Drug Therapy, Combination
MH  - Helicobacter Infections/*drug therapy
MH  - Helicobacter pylori/drug effects
MH  - Humans
MH  - *Proton Pump Inhibitors/pharmacology/therapeutic use
OTO - NOTNLM
OT  - antibiotic resistance
OT  - bismuth
OT  - dual therapy
OT  - hybrid therapy
OT  - sequential therapy
OT  - triple therapy
OT  - vonoprazan
EDAT- 2020/09/13 06:00
MHDA- 2021/07/02 06:00
CRDT- 2020/09/12 05:35
PHST- 2020/09/12 05:35 [entrez]
PHST- 2020/09/13 06:00 [pubmed]
PHST- 2021/07/02 06:00 [medline]
AID - 10.1111/hel.12743 [doi]
PST - ppublish
SO  - Helicobacter. 2020 Sep;25 Suppl 1:e12743. doi: 10.1111/hel.12743.